http___metro-portal.hr_u-hrvatsku-stiglo-cjepivo-protiv-raka_12804_1.xml
1.1 2.1 3.1 4.1 5.1 6.1 7.1 8.1 9.1 10.1 11.1 12.1 13.1 14.1 15.1 16.1 17.1 18.1 19.1 20.1 21.1 22.1
Controversy revived by Gardasil the anti-cancer vaccine Newscast Media PARIS—The anti-cervical cancer vaccine ‘Gardasil’ ignited debate over the weekend after French teenager Marie-Oceane Bourguignon filed a lawsuit against French pharmaceutical company Sanofi Pasteur and the country’s health regulators. She claimed that extreme side-effects were caused by injections of Gardasil, a vaccine against the human papilloma virus (HPV), when she was 15 years old. Gardasil is made by Merck and sold throughout Europe by Sanofi. Bourguignon is suffering from either an evolutive nervous system disease or multiple sclerosis since February 2011, that she says is caused by the two vaccine injections she had in October and December 2010. However, Daniel Floret, the chair of the national committee that oversees vaccinations, said Monday that there is no evidence linking Gardasil with serious auto-immune conditions such as multiple sclerosis. Three other women have announced that they will lodge a complaint against Sanofi Pasteur over the alleged side-effects of Gardasil within the next two weeks. But proponents of the vaccine say 2.3 million teenagers are targeted preventively each year in France. About 3,000 women will suffer from a cervical cancer every year. Source: Radio France Internationale http://newscastmedia.com/gardasil.htm Categories: News Tags: Gardasil, herpes vaccine, hpv, human papilloma virus
1.1 2.1 3.1 3.2 3.3 4.1 5.1 6.1 7.1 8.1 9.1 9.2 9.3
U Hrvatsku stiglo cjepivo protiv raka Cervarix je cjepivo protiv raka grlića maternice, a istovremeno štiti od HPV-a, najčešćeg uzročnika Cjepivo protiv raka vrata maternice Cervarix od danas je dostupno u Hrvatskoj, priopćila je farmaceutska tvrtka GlaxoSmithKline d.o.o. Hrvatska (GSK). Odobrenje za stavljanje u promet cjepiva na hrvatsko tržište nedavno je izdala Agencija za lijekove RH. Cjepivo Cervarix indicirano je za prevenciju cervikalne intraepitelne neoplazije visokog stupnja (CIN 2. i 3. stupnja) te raka vrata maternice, uzročno povezanog sa humanim papiloma virusom (HPV) tipa 16 i 18. Preporučena maloprodajna cijena cjepiva je 910 kuna. Posljednje kliničke studije pokazale su da Cervarix osigurava stopostotnu zaštitu od dva tipa virusa HPV-a koji uzrokuju 70 posto karcinoma vrata maternice, zabilježenih u žena diljem svijeta. Cjepivo sadrži inovativni adjuvantni sustav AS04, osmišljen na način da potakne imunološki odgovor domaćina i produlji trajanje zaštite od infekcije tipovima virusa koji uzrokuju rak. Studije su pokazale da je cjepivo imunogeno bez obzira na životnu dob, te se njime postižu visoke razine protutijela u žena širokog dobnog raspona od 10 do 55 godina. Cervarix je odobren u 80 država svijeta uključujući i zemlje EU. Osim Cervarixa, na hrvatskom je tržištu dostupno i cjepivo protiv HPV-a Gardasil, farmaceutske tvrtke Merck. (hina/metro-portal)